What is Leerink Partnrs’ Estimate for CRBU FY2025 Earnings?

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Equities research analysts at Leerink Partnrs upped their FY2025 earnings per share estimates for Caribou Biosciences in a research report issued to clients and investors on Tuesday, August 12th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings of ($1.57) per share for the year, up from their prior estimate of ($1.64). The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share. Leerink Partnrs also issued estimates for Caribou Biosciences’ Q4 2025 earnings at ($0.38) EPS, FY2026 earnings at ($1.73) EPS, FY2027 earnings at ($1.82) EPS, FY2028 earnings at ($2.14) EPS and FY2029 earnings at ($0.81) EPS.

CRBU has been the subject of a number of other research reports. HC Wainwright restated a “buy” rating and set a $3.00 target price (down previously from $9.00) on shares of Caribou Biosciences in a report on Monday, April 28th. Wall Street Zen lowered Caribou Biosciences from a “hold” rating to a “sell” rating in a report on Saturday.

Caribou Biosciences Stock Down 1.0%

Caribou Biosciences stock opened at $1.98 on Friday. The business has a fifty day moving average of $1.67 and a two-hundred day moving average of $1.25. The firm has a market cap of $184.38 million, a P/E ratio of -1.11 and a beta of 2.55. Caribou Biosciences has a twelve month low of $0.66 and a twelve month high of $3.00.

Caribou Biosciences (NASDAQ:CRBU) last posted its earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.05. The company had revenue of $2.67 million during the quarter, compared to analyst estimates of $1.64 million. Caribou Biosciences had a negative return on equity of 62.35% and a negative net margin of 1,800.93%.

Hedge Funds Weigh In On Caribou Biosciences

Large investors have recently made changes to their positions in the business. Next Capital Management LLC acquired a new position in shares of Caribou Biosciences during the second quarter worth $25,000. Creative Planning acquired a new position in shares of Caribou Biosciences during the second quarter worth $25,000. Hudson Bay Capital Management LP acquired a new position in shares of Caribou Biosciences during the second quarter worth $30,000. Russell Investments Group Ltd. increased its position in shares of Caribou Biosciences by 859.0% during the fourth quarter. Russell Investments Group Ltd. now owns 23,909 shares of the company’s stock worth $38,000 after purchasing an additional 21,416 shares in the last quarter. Finally, MetLife Investment Management LLC increased its position in shares of Caribou Biosciences by 60.0% during the fourth quarter. MetLife Investment Management LLC now owns 24,404 shares of the company’s stock worth $39,000 after purchasing an additional 9,148 shares in the last quarter. 77.51% of the stock is owned by institutional investors and hedge funds.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.